BUZZ-JonesTrading raises PT on Monopar Therapeutics after AstraZeneca agreement

Reuters11-20

BUZZ-JonesTrading raises PT on <a href="https://laohu8.com/S/MNPR">Monopar Therapeutics</a> after AstraZeneca agreement

** JonesTrading raises PT on drug developer Monopar Therapeutics MNPR.O to $37 from $9

** Brokerage says MNPR signed agreement with AstraZeneca AZN.L unit Alexion for exclusive worldwide licensing of ALXN-1840 for the treatment of Wilson's disease

** Wilson's disease is a rare genetic condition that causes the buildup of copper to toxic levels

** JonesTrading says ALXN-1840 has the potential to give MNPR a steady cash flow to fund other development efforts

** Brokerage reiterates "buy" rating; PT of $37 is ~94.6% upside on stock's last close

** All of three brokerages rate the stock "buy"; their median PT is $23 - LSEG data

** As of last close, stock up ~1,017.6% YTD

(Reporting by Prakhar Srivastava in Bengaluru)

((Prakhar.srivastava2@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484111865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484111865","market":"us","top_or_hot":-1,"title":"BUZZ-JonesTrading raises PT on Monopar Therapeutics after AstraZeneca agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-JonesTrading raises PT on <a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> after AstraZeneca agreement</title></head><body><p>** JonesTrading raises PT on <span>drug developer </span>Monopar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>MNPR.O</span> to $37 from $9</p><p>** Brokerage says MNPR signed agreement with AstraZeneca <span>AZN.L</span> unit Alexion for exclusive worldwide licensing of ALXN-1840 for the treatment of Wilson's disease</p><p>** <span>Wilson's disease</span> is a rare genetic condition that causes the buildup of <span>copper to toxic levels</span></p><p>   ** JonesTrading <span>says </span>ALXN-1840 has the potential to <span>give </span>MNPR a steady cash flow to fund other development efforts</p><p>** Brokerage reiterates \"buy\" rating; PT of $37 is ~94.6% upside on stock's last close</p><p>** All of three brokerages rate the stock \"buy\"; their median PT is $23 - LSEG data</p><p>** <span>As of last close</span>, stock up ~1,017.6% YTD</p><p> (Reporting by Prakhar Srivastava in Bengaluru)</p><p> ((Prakhar.srivastava2@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-JonesTrading raises PT on Monopar Therapeutics after AstraZeneca agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-JonesTrading raises PT on Monopar Therapeutics after AstraZeneca agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR0UJ:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-JonesTrading raises PT on Monopar Therapeutics after AstraZeneca agreement** JonesTrading raises PT on drug developer Monopar Therapeutics MNPR.O to $37 from $9** Brokerage says MNPR signed ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR0UJ:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR0UJ:1","article_id":"2484111865","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484111865","pubTimestamp":1732106493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-JonesTrading raises PT on Monopar Therapeutics after AstraZeneca agreement** JonesTrading raises PT on drug developer Monopar Therapeutics MNPR.O to $37 from $9** Brokerage says MNPR signed agree","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics","BK4139":"生物科技"},"translate_title":"阿斯利康协议后BUZZ-JonesTrading提高Monopar Therapeutics的PT","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":0.9},"content_text":"BUZZ-JonesTrading raises PT on Monopar Therapeutics after AstraZeneca agreement** JonesTrading raises PT on drug developer Monopar Therapeutics MNPR.O to $37 from $9** Brokerage says MNPR signed agreement with AstraZeneca AZN.L unit Alexion for exclusive worldwide licensing of ALXN-1840 for the treatment of Wilson's disease** Wilson's disease is a rare genetic condition that causes the buildup of copper to toxic levels   ** JonesTrading says ALXN-1840 has the potential to give MNPR a steady cash flow to fund other development efforts** Brokerage reiterates \"buy\" rating; PT of $37 is ~94.6% upside on stock's last close** All of three brokerages rate the stock \"buy\"; their median PT is $23 - LSEG data** As of last close, stock up ~1,017.6% YTD (Reporting by Prakhar Srivastava in Bengaluru) ((Prakhar.srivastava2@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484111865"}